Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma
30.11.2021 13:00:00 CET | LEO Pharma | Press release
LEO Pharma has recently completed the first phase of its strategic transformation process – including the development of a new capital and governance structure. During her more than two years as President and CEO, Catherine Mazzacco has successfully led this effort and developed the company’s sales and marketing capabilities while at the same time building a strong executive leadership team.
The next phase of LEO Pharma’s transformation is focused on preparing the company for an IPO within a four- to five-year time horizon. This requires a focus on operational efficiency, shareholder and capital markets engagement, and driving the internal strategic transformation of the organization.
The Board of Directors and Catherine Mazzacco have together concluded that this would be the right time for LEO Pharma to recruit a new CEO. Catherine Mazzacco is stepping down from her role and leaving the company on November 30, 2021.
Catherine Mazzacco says:
“It has been a privilege to be the CEO of LEO Pharma and I have a tremendous affection for LEO Pharma employees and their high level of engagement for the company. I am proud of the accomplishments we have achieved together in setting an ambitious strategy for the company, completing a comprehensive efficiency improvement program, establishing a new capital structure and advancing the launch of a major new therapy.”
The Chairman of the Board, Jesper Brandgaard, says:
“On behalf of the Board, I would like to express our sincere thanks to Catherine Mazzacco for her commendable efforts in leading the transformation of LEO Pharma towards a leadership position in the innovative space of medical dermatology. Catherine Mazzacco has been instrumental in driving the company’s ambitious growth strategy towards 2030.”
The Board of Directors has initiated a search process for the next CEO. Until a new permanent CEO is in place, the current LEO Pharma CFO, Anders Kronborg, will step in as acting CEO, and the Chairman of the Board, Jesper Brandgaard, will act as Executive Chair.
Contacts
Karen Frost
+45 3166 1567
KASFR@leo-pharma.com
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 million.
For more information, please visit www.LEO-Pharma.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma delivers 10% revenue growth at CER and strengthens late-stage pipeline18.8.2026 09:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 18 August, 2026 – In H1 2026, LEO Pharma delivered strong revenue growth, driven by the dermatology portfolio, with an improved gross margin alongside significantly increased investments in commercial and innovation activities. In August, LEO Pharma agreed to acquire the global rights for dersimelagon, an investigational first-in-class oral therapy with potential launch in 2027. Together with the acquisition of Replay, announced in April 2026, the agreement further strengthens LEO Pharma’s pipeline in rare genetic skin diseases. Financial highlights LEO Pharma’s revenue increased by 7% to DKK 7,257 million, and by 10% at constant exchange rates (CER). The revenue growth was led by North America (38% at CER) and Rest of World (10% at CER), while sales in Europe (0% at CER) were broadly stable compared to H1 2025. Revenue from the Dermatology portfolio grew by 12% (CER), driven by the strategic brands Anzupgo®, Spevigo® and Adtralza®/Adbry®, which combined had a revenu
LEO Pharma further strengthens late-stage pipeline with the acquisition of dersimelagon18.8.2026 08:58:00 CEST | Pressemeddelelse
Acquisition adds dersimelagon to LEO Pharma’s rare dermatology pipeline, an investigational once-daily oral melanocortin 1 receptor (MC1R) agonist for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) that has completed Phase 3 development and for which a New Drug Application (NDA) has been submitted to U.S. Food and Drug Administration (FDA) for review in June 2026.1 Leverages LEO Pharma's six decades of dermatology expertise to advance innovation for patients with rare skin diseases through the addition of this oral late-stage asset, building on LEO Pharma’s recent acquisition of Replay and partnership with Boehringer Ingelheim for Spevigo® (spesolimab). EPP and XLP are rare, devastating lifelong genetic disorders that cause severe sunlight-induced skin pain, as well as rash, swelling, redness, burning sensations and, in some cases, liver damage.2,3 Under the terms of the agreement, LEO Pharma will acquire worldwide rights to dersimelagon from Tanabe Pharma for up
LEO Pharma elects Henriette Mersebach to the Board of Directors14.8.2026 09:00:00 CEST | Pressemeddelelse
Henriette Mersebach will bring deep pharmaceutical R&D and innovation expertise to the Board
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis9.7.2026 17:00:00 CEST | Pressemeddelelse
TRAPEDS-1 is a Phase 2 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.1 The pharmacokinetic profile was as expected and consistent with what has previously been observed with tralokinumab. Tralokinumab was generally well tolerated for up to 172 weeks of treatment, with no new safety signals identified.
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen25.6.2026 13:00:00 CEST | Pressemeddelelse
New data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1 Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom